This site is intended for healthcare professionals
News

Myovant Sciences has submitted an NDA to the FDA for its once-daily relugolix for the treatment of women with heavy menstrual bleeding associated with uterine fibroids.

Read time: 1 mins
Last updated:3rd Jun 2020
Published:3rd Jun 2020
Condition: Uterine Fibroids
Type: drug
Register free for full access to medthority.com